
    
      100 patients with Rheumatoid Arthritis (RA), 50 patients with Systemic Lupus Erythematosus
      (SLE), 50 patients with spondyloarthropathies (Psoriatic arthritis (PsA) and Ankylosing
      Spondylitis (AS) and 200 healthy subjects will participate in the study.

      All the subjects will be vaccinated with Focetria (Novartis) and will be evaluated the day of
      vaccination and 4 weeks later.

      The evaluation will include:

      Efficacy of the vaccine: Blood will be drawn on day 0 and 4 weeks later and tested for the
      presence of antibodies against A/California17/2009/H1N1 by hemagglutination inhibition test.

      Safety of the vaccine:

        -  Records of adverse event

        -  Assessment of disease activity : RA - Disease activity score (DAS 28), SLE - SLEDAI, PsA
           - DAS 28 and PASI, AS- BASDAI, ESR, CRP
    
  